Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2023

Open Access 01-12-2023 | Insulins | Research

Effect of Orlistat on anthropometrics and metabolic indices in children and adolescents: a systematic review and meta-analysis

Authors: Zeinab Nikniaz, Leila Nikniaz, Mahdieh Abbasalizad Farhangi, Hossein Mehralizadeh, Shabnam Salekzamani

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Background

Childhood obesity is one of the main concerns of public health. Considering its long-term adverse health effect, various studies investigated the effect of drug therapy on anthropometric parameters and provided mixed results. In this systematic review and meta-analysis, we aimed to determine the effect of Orlistat on anthropometrics and biochemical parameters in children and adolescents.

Materials and methods

The databases of PubMed, Scopus, and Web of Science were searched until September 2022. Experimental and semi-experimental studies were included if they evaluated the effect of Orlistat on obesity-related parameters in children and reported the before and after anthropometric values. A revised Cochrane risk-of-bias (Rob2) was used to evaluate the methodological quality. STATA software version 16.0 was used for the meta-analysis of the random-effect model.

Results

Of 810 articles retrieved in the initial search, four experimental and two semi-experimental studies were selected for systematic review. The result of the meta-analysis of experimental studies indicated the significant effect of Orlistat on waist circumference (SMD: -0.27, 95% CI: -0.47, -0.07) and serum insulin level (SMD: -0.89, 95% CI: -1.52, 0.26). However, there were no significant effects of orlistat on body weight, body mass index, lipid profile, and serum glucose level.

Conclusion

The present meta-analysis showed the significant effect of Orlistat on the reduction of waist circumference and insulin level in overweight and obese adolescents. However, due to the paucity of studies included in the meta-analysis, more prospective studies with longer duration and more sample sizes will be needed in this age group.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Reilly JJ. Low levels of objectively measured physical activity in preschoolers in child care. Med Sci Sports Exerc. 2010;42(3):502–7.CrossRefPubMed
4.
Lindberg L, Danielsson P, Persson M, Marcus C, Hagman E. Association of childhood obesity with risk of early all-cause and cause-specific mortality: a swedish prospective cohort study. PLoS Med. 2020;17(3):e1003078.CrossRefPubMedPubMedCentral
5.
Anderson PM, Butcher KF. Childhood obesity: trends and potential causes. The Future of children 2006:19–45.
6.
Gibson LJ, Peto J, Warren JM, Silva IdS. Lack of evidence on diets for obesity for children: a systematic review. Int J Epidemiol. 2006;35(6):1544–52.CrossRefPubMed
7.
Zhi J, Melia A, Guerciolini R, Chung J, Kinberg J, Hauptman J, Patel I. Retrospective population-based analysis of the dose‐response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994;56(1):82–5.CrossRefPubMed
8.
Influence of body mass index on prescribing costs. And potential cost savings of a weight management programme in primary care. J Health Serv Res Policy. 2008;13(3):158–66.CrossRef
9.
Dombrowski SU, Knittle K, Avenell A, Araújo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ 2014, 348.
10.
Peirson L, Fitzpatrick-Lewis D, Morrison K, Warren R, Usman Ali M, Raina P. Treatment of overweight and obesity in children and youth: a systematic review and meta-analysis. CMAJ Open. 2015;3(1):E35–46.CrossRefPubMedPubMedCentral
11.
Holmbäck U, Grudén S, Litorp H, Willhems D, Kuusk S, Alderborn G, Söderhäll A, Forslund A. Effects of a novel weight-loss combination product containing orlistat and acarbose on obesity: a randomized, placebo-controlled trial. Obes (Silver Spring). 2022;30(11):2222–32.CrossRef
12.
Viner R, Hsia Y, Tomsic T, Wong I. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta‐analysis. Obes Rev. 2010;11(8):593–602.CrossRefPubMed
13.
Zhao G, Zhang Q, Wu F, Yin S, Xie Y, Liu H. Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 2022:1–7.
14.
Yu CC, Li AM, Chan KO, Chook P, Kam JT, Au CT, So RC, Sung RY, McManus AM. Orlistat improves endothelial function in obese adolescents: a randomised trial. J Paediatr Child Health. 2013;49(11):969–75.CrossRefPubMed
15.
Maahs D, de Serna DG, Kolotkin RL, Ralston S, Sandate J, Qualls C, Schade DS. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract. 2006;12(1):18–28.CrossRefPubMed
16.
17.
Duval S, Tweedie R. Trim and fill: a simple funnel-plot–based method of testing and adjusting for publication bias in meta‐analysis. Biometrics. 2000;56(2):455–63.CrossRefPubMed
18.
Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr. 2004;163(12):738–41.CrossRefPubMed
19.
Norgren S, Danielsson P, Jurold R, Lötborn M, Marcus C. Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatr. 2003;92(6):666–70.CrossRefPubMed
20.
McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res. 2002;10(7):642–50.CrossRefPubMed
21.
Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293(23):2873–83.CrossRefPubMed
22.
Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532–46.CrossRefPubMed
23.
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the Prevention of Diabetes in obese subjects (XENDOS) study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Clin Diabetol. 2004;5(2):95–104.
24.
Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281(3):235–42.CrossRefPubMed
25.
Sjostrom L, Andersen T. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet. 1998;352(9123):167–72.CrossRef
26.
Chilton M, Dunkley A, Carter P, Davies M, Khunti K, Gray L. The effect of antiobesity drugs on waist circumference: a mixed treatment comparison. Diabetes Obes Metabolism. 2014;16(3):237–47.CrossRef
27.
Butterworth J, Deguara J, Borg C-M. Bariatric surgery, polycystic ovary syndrome, and infertility. Journal of obesity 2016, 2016.
28.
29.
Sahebkar A, Simental-Mendia LE, Reiner Ž, Kovanen PT, Simental-Mendia M, Bianconi V, Pirro M. Effect of orlistat on plasma lipids and body weight: a systematic review and meta-analysis of 33 randomized controlled trials. Pharmacol Res. 2017;122:53–65.CrossRefPubMed
30.
Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care. 2004;27(1):33–40.CrossRefPubMed
31.
Tiikkainen M, Bergholm R, Rissanen A, Aro A, Salminen I, Tamminen M, Teramo K, Yki-Järvinen H. Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutr. 2004;79(1):22–30.CrossRefPubMed
32.
Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JP, Sjöström L. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160(9):1321–6.CrossRefPubMed
33.
Hirosawa K, Fukami T, Nakano M, Nakajima M. Evaluation of drug-drug interactions via inhibition of hydrolases by orlistat, an anti-obesity drug. Drug Metab Dispos 2023.
Metadata
Title
Effect of Orlistat on anthropometrics and metabolic indices in children and adolescents: a systematic review and meta-analysis
Authors
Zeinab Nikniaz
Leila Nikniaz
Mahdieh Abbasalizad Farhangi
Hossein Mehralizadeh
Shabnam Salekzamani
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01390-7

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue

Research

Sensitivity to thyroid hormone indices are associated with papillary thyroid carcinoma in Chinese patients with thyroid nodules

Research

Comparing the effectiveness of metformin with lifestyle modification for the primary prevention of type II diabetes: a systematic review and meta-analysis

Research

Metabolic syndrome among people living with HIV on antiretroviral therapy in Mwanza, Tanzania

Research

Effect of educational intervention programme on the health-related quality of life (HRQOL) of individuals with type 2 diabetes mellitus in South-East, Nigeria

Research

Systematic review of the effect of caffeine therapy effect on cardiometabolic markers in rat models of the metabolic syndrome

Research

A high Diabetes Risk Reduction Score (DRRS) is associated with a better cardio-metabolic profile among obese individuals
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits